Study of Carvedilol Treatment to Reduce Portal Pressure in Cirrhosis Measured by Endoscopic Ultrasound

What this Trial Is About

Researchers are evaluating the effect of Carvedilol in preventing digestive bleeding caused by portal hypertension in people with cirrhosis. The study aims to measure how well Carvedilol lowers the pressure gradient in the portal vein system using a specialized ultrasound technique. This investigation is conducted in a clinical setting to assess changes after one month of treatment. Participants will receive Carvedilol orally starting with 3.125 mg on the first day, increasing to 6.25 mg daily from day 2 to day 8, then 12.5 mg daily from day 9 to day 90. Several study visits include clinical exams, blood pressure and pulse monitoring, electrocardiograms if needed, and assessments of treatment adherence. Endoscopic ultrasound measurements will be done at the beginning and around day 30 to evaluate the portal pressure. Throughout the study, participants will have regular check-ups to monitor their health, possible side effects, and response to the medication. Researchers will track any digestive hemorrhages occurring within three months and review heart and vital sign data. The total participation lasts about three months, with continued treatment and follow-up care planned according to standard medical practice after the study ends.

CARPEUS : Effect of Carvedilol on the Portosystemic Gradient as Measured by Endoscopic Ultrasound